The Combination of Fosfomycin, Metronidazole, and Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor is Stable in vitro and Has Maintained Antibacterial Activity

Abstract

Background Treatment of secondary peritonitis includes surgery and antimicrobial agents. Antimicrobial agents are often administered intravenously, however, the alternative route intraperitoneal administration could be considered. Investigations must be conducted prior to clinical application. Therefore, we aimed to investigate the combination of fosfomycin, metronidazole, and recombinant human granulocyte-macrophage colony-stimulating factor with regard to its chemical properties and the solution’s stability. In addition, the antibacterial effect of the mixed drug solution was compared with the effect of the individual antibacterial agents.

Methods The drugs were mixed to an aqueous solution. Basic chemical investigations of pH, precipitation, and calculated osmolarity of the drug combination were conducted. Fosfomycin and metronidazole’s chemical stability was investigated using High Pressure Liquid Chromatography-Mass Spectrometry. Microbiological investigations using the agar cup method were carried out to measure the antibacterial effect of fosfomycin and metronidazole.

Results The aqueous solution of the combination of the three drugs had a pH of 7.46–7.62, which was stable during 24 h, was without precipitation, and had a calculated osmolarity of 293 mOsm/l. High Pressure Liquid Chromatography-Mass Spectrometry found stable concentrations of fosfomycin and metronidazole both alone and in combination during 24 h. The antibacterial effect of the drug combination solution was similar to the antibacterial effects of fosfomycin and metronidazole alone.

Conclusion The drug combination had neutral and stable pH, was iso-osmotic, and had stable concentrations during 24 h of storage. The antibacterial effect of fosfomycin and metronidazole were not altered when the drugs were mixed.

Key words

Antibacterial drugs - inflammation - chemistry

• References

• 1 O’Neal PB, Itani KMF. Antimicrobial formulation and delivery in the prevention of surgical site infection. Surg Infect (Larchmt) 2016; 17: 275-285
• 2 Hasper D, Schefold JC, Baumgart DC. Management of severe abdominal infections. Recent Pat Antiinfect Drug Discov 2009; 4: 57-65
• 3 Ballinger AE, Palmer SC, Wiggins KJ. et al. Treatment for peritoneal dialysis-associated peritonitis. Cochrane Database Syst Rev 2014; 4: CD005284
• 4 Malangoni MA, Inui T. Peritonitis – the Western experience. World J Emerg Surg 2006; 1: 25
• 5 Tobudic S, Matzneller P, Stoiser B. et al. Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis. Antimicrob Agents Chemother 2012; 56: 3992-3995
• 6 Saha SK. Efficacy of metronidazole lavage in treatment of intraperitoneal sepsis. A prospective study. Dig Dis Sci 1996; 41: 1313-1318
• 7 Saha SK. Peritoneal lavage with metronidazole. Surg Gynecol Obstet 1985; 160: 335-338
• 8 El-Sefi TA, El-Awady HM, Shehata MI. et al. Systemic plus local metronidazole and cephazolin in complicated appendicitis: A prospective controlled trial. J R Coll Surg Edinb 1989; 34: 13-16
• 9 Selgas R, Fernández de Castro M, Jiménez C. et al Immunomodulation of peritoneal macrophages by granulocyte-macrophage colony-stimulating factor in humans. Kidney Int 1996; 50: 2070-2078
• 10 Toner GC, Gabrilove JL, Gordon M. et al. Phase I trial of intravenous and intraperitoneal administration of granulocyte-macrophage colony-stimulating factor. J Immunother Emphasis Tumor Immunol 1994; 15: 59-66
• 11 Drugbank. http://www.drugbank.ca/drugs/DB00828 last accessed 31-08-2017)
• 12 Raz R. Fosfomycin: an old-new antibiotic. Clin Microbiol Infect 2012; 18: 4-7
• 13 PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/446987#section = 2D-Structure (last accessed 31-08- 2017)
• 14 Kahan FM, Kahan JS, Cassidy PJ. et al. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 1974; 235: 364-386
• 15 Lamp KC, Freeman CD, Klutman NE. et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999; 36: 353-373
• 16 Drugbank. http://www.drugbank.ca/drugs/DB00916 (last accessed 31-08-2017)
• 17 Liles WC, Van Voorhis WC. Review: Nomenclature and biologic significance of cytokines involved in inflammation and the host immune response. J Infect Dis 1995; 172: 1573-1580
• 18 Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 1992; 327: 28-35
• 19 Weisbart RH, Gasson JC, Golde DW. Physiology of granulocyte and macrophage colony-stimulating factors in host defense. Hematol Oncol Clin North Am 1989; 3: 401-409
• 20 Orozco H, Arch J, Medina-Franco H. et al. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: A randomized, double-blind, placebo-controlled clinical trial. Arch Surg 2006; 141: 150-154
• 21 Presneill JJ, Harris T, Stewart AG. et al. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002; 166: 138-143
• 22 Yamamoto T, Sakakura T, Yamakawa M. et al. Clinical effects of long-term use of neutralized dialysate for continuous ambulatory peritoneal dialysis. Nephron 1992; 60: 324-329
• 23 Rose SB, Miller RE. Studies with the agar cup-plate method: I. A standardized agar cup-plate technique. J Bacteriol 1939; 38: 525-537
• 24 Bang J. Zone formation in the agar-cup method for determining resistance to antibiotics. Acta Pathol Microbiol Scand Suppl 1956; 39: 192-193
• 25 Trissel LA, Bready BB, Kwan JW. et al. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992; 49: 402-406
• 26 Prakash J, Tripathi K, Singh M. Complications of intermittent peritoneal dialysis. J Assoc Physicians India 1990; 38: 906-908
• 27 Rippe B, Simonsen O, Wieslander A. et al. Clinical and physiological effects of a new, less toxic and less acidic fluid for peritoneal dialysis. Perit Dial Int 1997; 17: 27-34
• 28 Mactier RA, Sprosen TS, Gokal R. et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53: 1061-1067
• 29 Williams JD, Craig KJ, Topley N. et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479
• 30 Williams JD, Topley N, Craig KJ. et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418
• 31 Ayuzawa N, Ishibashi Y, Takazawa Y. et al. Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: Recent clinical practice in Japan. Perit Dial Int 2012; 32: 159-167
• 32 Kussmann M, Baumann A, Hauer S. et al. Compatibility of fosfomycin with different commercial peritoneal dialysis solutions. Eur J Clin Microbiol Infect Dis. 2017; 36: 2237-2242
• 33 Quentin C, Bouchet JJ, Gaillard I. et al. Stability of fosfomycin and quinolones in peritoneal dialysis solution. J Antimicrob Chemother 1990; 25: 878-880